Tempest Therapeutics

Update in progress

TPST (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule cancer therapies. Its lead candidates are Amezalpat, an oral selective PPARα antagonist for first-line unresectable or metastatic hepatocellular carcinoma, which completed Phase 2, and TPST-1495, a dual EP2/EP4 receptor antagonist targeting prostaglandin E2 for various cancers. The company has a Roche collaboration to advance Amezalpat in a global first-line trial and is headquartered in Brisbane, California.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive